Outpatient Management of Stable Acute Pulmonary Embolism: Proposed Accelerated Pathway for Risk Stratification

American Journal of Medicine

Volumn 120, Issue 10 SUPPL. 2, 2007, Pages

  AlMahameed, Amjad ^a   Carman, Teresa L ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Anticoagulation; Pharmacotherapy; Pulmonary embolism; Risk stratification; Treatment; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; NADROPARIN; TINZAPARIN; WARFARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL ASSESSMENT; CLINICAL FEATURE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; COST BENEFIT ANALYSIS; DEEP VEIN THROMBOSIS; DEMOGRAPHY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; ELECTROCARDIOGRAPHY; EMBOLECTOMY; FOLLOW UP; HOSPITALIZATION; HUMAN; LUNG EMBOLISM; LUNG FUNCTION TEST; LUNG VENTILATION; MORTALITY; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; RISK ASSESSMENT; THROMBOCYTOPENIA; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VENA CAVA FILTER;

ALGORITHMS; AMBULATORY CARE; ANTICOAGULANTS; FIBRINOLYTIC AGENTS; HUMANS; OUTPATIENTS; PATIENT SELECTION; PRACTICE GUIDELINES; PULMONARY EMBOLISM; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 34748885520     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2007.08.010     Document Type: Article

References (62)

1. White R.H. The epidemiology of venous thromboembolism. Circulation 107 suppl 1 (2003) I4-I18
2. Meignan M., Rosso J., Gauthier H., et al. Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis. Arch Intern Med 160 (2000) 159-164
3. Bates S.M., and Ginsberg J.S. Clinical practice: treatment of deep-vein thrombosis. N Engl J Med 351 (2004) 268-277
4. Buller H.R., Agnelli G., Hull R.D., Hyers T.M., Prins M.H., and Raskob G.E. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 suppl 3 (2004) 401S-428S
5. Heit J., Cohen A., and Anderson F.A. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. [abstract]. Blood (2005) 102
6. Pineda L.A., Hathwar V.S., and Grant B.J. Clinical suspicion of fatal pulmonary embolism. Chest 120 (2001) 791-795
7. Stein P.D., and Henry J.W. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 108 (1995) 978-981
8. Merli G.J. Pulmonary embolism in medical patients: improved diagnosis and the role of low-molecular-weight heparin in prevention and treatment. J Thromb Thrombolysis 18 (2004) 117-125
9. Douketis J.D. Prognosis in pulmonary embolism. Curr Opin Pulm Med 7 (2001) 354-359
10. Wood K.E. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest 121 (2002) 877-905
11. Goldhaber S.Z., Visani L., and De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 353 (1999) 1386-1389
12. Lim K.E., Chan C.Y., Chu P.H., Hsu Y.Y., and Hsu W.C. Right ventricular dysfunction secondary to acute massive pulmonary embolism detected by helical computed tomography pulmonary angiography. Clin Imaging 29 (2005) 16-21
13. Aujesky D., Obrosky D.S., Stone R.A., et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 172 (2005) 1041-1046
14. Heit J.A., Silverstein M.D., Mohr D.N., Petterson T.M., O'Fallon W.M., and Melton III L.J. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 159 (1999) 445-453
15. Nendaz M.R., Bandelier P., Aujesky D., et al. Validation of a risk score identifying patients with acute pulmonary embolism, who are at low risk of clinical adverse outcome. Thromb Haemost 91 (2004) 1232-1236
16. Wicki J., Perrier A., Perneger T.V., Bounameaux H., and Junod A.F. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost 84 (2000) 548-552
17. Konstantinides S., Geibel A., Kasper W., Olschewski M., Blumel L., and Just H. Patent foramen ovale is an important predictor of adverse outcome in patients with major pulmonary embolism. Circulation 97 (1998) 1946-1951
18. Goldhaber S.Z. Echocardiography in the management of pulmonary embolism. Ann Intern Med 136 (2002) 691-700
19. Goldhaber S.Z., and Elliott C.G. Acute pulmonary embolism: part II. Risk stratification, treatment, and prevention. Circulation 108 (2003) 2834-2838
20. Kucher N., Rossi E., De Rosa M., and Goldhaber S.Z. Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mm Hg or higher. Arch Intern Med 165 (2005) 1777-1781
21. Quiroz R., Kucher N., Schoepf U.J., et al. Right ventricular enlargement on chest computed tomography: prognostic role in acute pulmonary embolism. Circulation 109 (2004) 2401-2404
22. Schoepf U.J., Kucher N., Kipfmueller F., Quiroz R., Costello P., and Goldhaber S.Z. Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation 110 (2004) 3276-3280
23. van der Meer R.W., Pattynama P.M., van Strijen M.J., et al. Right ventricular dysfunction and pulmonary obstruction index at helical CT: prediction of clinical outcome during 3-month follow-up in patients with acute pulmonary embolism. Radiology 235 (2005) 798-803
24. Binder L., Pieske B., Olschewski M., et al. N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation 112 (2005) 1573-1579
25. Kostrubiec M., Pruszczyk P., Bochowicz A., et al. Biomarker-based risk assessment model in acute pulmonary embolism. Eur Heart J 26 (2005) 2166-2172
26. Kucher N., Printzen G., Doernhoefer T., Windecker S., Meier B., and Hess O.M. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation 107 (2003) 1576-1578
27. Grifoni S., Olivotto I., Cecchini P., et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation 101 (2000) 2817-2822
28. Ribeiro A., Lindmarker P., Juhlin-Dannfelt A., Johnsson H., and Jorfeldt L. Echocardiography Doppler in pulmonary embolism: right ventricular dysfunction as a predictor of mortality rate. Am Heart J 134 (1997) 479-487
29. Kucher N., and Goldhaber S.Z. Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. Circulation 108 (2003) 2191-2194
30. Geibel A., Zehender M., Kasper W., Olschewski M., Klima C., and Konstantinides S.V. Prognostic value of the ECG on admission in patients with acute major pulmonary embolism. Eur Respir J 25 (2005) 843-848
31. Giannitsis E., Muller-Bardorff M., Kurowski V., et al. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism. Circulation 102 (2000) 211-217
32. Meyer T., Binder L., Hruska N., Luthe H., and Buchwald A.B. Cardiac troponin I elevation in acute pulmonary embolism is associated with right ventricular dysfunction. J Am Coll Cardiol 36 (2000) 1632-1636
33. Tulevski I., Hirsch A., Sanson B.J., et al. Increased brain natriuretic peptide as a marker for right ventricular dysfunction in acute pulmonary embolism. Thromb Haemost 86 (2001) 1193-1196
34. Konstantinides S., Geibel A., Olschewski M., et al. Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism. Circulation 106 (2002) 1263-1268
35. Mehta N.J., Jani K., and Khan I.A. Clinical usefulness and prognostic value of elevated cardiac troponin I levels in acute pulmonary embolism. Am Heart J 145 (2003) 821-825
36. Pruszczyk P., Bochowicz A., Torbicki A., et al. Cardiac troponin T monitoring identifies high-risk group of normotensive patients with acute pulmonary embolism. Chest 123 (2003) 1947-1952
37. Muller-Bardorff M., Weidtmann B., Giannitsis E., Kurowski V., and Katus H.A. Release kinetics of cardiac troponin T in survivors of confirmed severe pulmonary embolism. Clin Chem 48 (2002) 673-675
38. Piazza G., and Goldhaber S.Z. Acute pulmonary embolism: part II. Treatment and prophylaxis. Circulation 114 (2006) e42-e47
39. Guyatt G., Schunemann H.J., Cook D., Jaeschke R., and Pauker S. Applying the grades of recommendation for antithrombotic and thrombolytic therapy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 suppl 3 (2004) 179S-187S
40. Task Force on Pulmonary Embolism, European Society of Cardiology. Guidelines on diagnosis and management of acute pulmonary embolism. Eur Heart J 21 (2000) 1301-1336
41. Shapiro S.S. Treating thrombosis in the 21st century. N Engl J Med 349 (2003) 1762-1764
42. Hirsh J., Warkentin T.E., Shaughnessy S.G., et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119 suppl 1 (2001) 64S-94S
43. Wells P.S., Kovacs M.J., Bormanis J., et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection. Arch Intern Med 158 (1998) 1809-1812
44. Kovacs M.J., Anderson D., Morrow B., Gray L., Touchie D., and Wells P.S. Outpatient treatment of pulmonary embolism with dalteparin. Thromb Haemost 83 (2000) 209-211
45. Labas P., Ohradka B., and Cambal M. Could deep vein thrombosis be safely treated at home?. Bratisl Lek Listy 102 (2001) 458-461
46. Beer J.H., Burger M., Gretener S., Bernard-Bagattini S., and Bounameaux H. Outpatient treatment of pulmonary embolism is feasible and safe in a substantial proportion of patients. J Thromb Haemost 1 (2003) 186-187
47. Rhodes S., Bond S., Green S., et al. Outpatient management of pulmonary embolism: results from the national multicentre PE study. [abstract]. Blood 106 (2005) 911
48. Olsson C.G., Bitzen U., Olsson B., et al. Outpatient tinzaparin therapy in pulmonary embolism quantified with ventilation/perfusion scintigraphy. Med Sci Monit 12 (2006) PI9-PI3
49. Nutescu E.A., Shapiro N.L., Chevalier A., and Amin A.N. A pharmacologic overview of current and emerging anticoagulants. Cleve Clin J Med 72 suppl 1 (2005) S2-S6
50. Warkentin T.E., Maurer B., and Aster R.H. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 356 (2007) 2653-2655
51. Buller H.R., Davidson B.L., Decousus H., et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349 (2003) 1695-1702
52. Agnelli G., and Becattini C. Clinical and economic aspects of managing venous thromboembolism in the outpatient setting. Semin Hematol 38 (2001) 58-66
53. Wells P.S. Outpatient treatment of patients with deep-vein thrombosis or pulmonary embolism. Curr Opin Pulm Med 7 (2001) 360-364
54. Wells P.S., and Buller H.R. Outpatient treatment of patients with pulmonary embolism. Semin Vasc Med 1 (2001) 229-234
55. Segal J.B., Bolger D.T., Jenckes M.W., et al. Outpatient therapy with low molecular weight heparin for the treatment of venous thromboembolism: a review of efficacy, safety, and costs. Am J Med 115 (2003) 298-308
56. Ong B.S., Karr M.A., Chan D.K., Frankel A., and Shen Q. Management of pulmonary embolism in the home. Med J Aust 183 (2005) 239-242
57. Wells P.S., Anderson D.R., Rodger M.A., et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med 165 (2005) 733-738
58. Koopman M.M., Prandoni P., Piovella F., et al., Tasman Study Group. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 334 (1996) 682-687
59. Buller H., and MATISSE Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux: the MATISSE trials. Poster presented at the Annual Meeting of The International Society on Thrombosis and Haemostasis. August 6, Sydney, Australia (2005)
60. Aujesky D., Smith K.J., Cornuz J., and Roberts M.S. Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism. Chest 128 (2005) 1601-1610
61. Rodger M.A., Gagne-Rodger C., Howley H.E., Carrier M., Coyle D., and Wells P.S. The outpatient treatment of deep vein thrombosis delivers cost savings to patients and their families, compared to inpatient therapy. Thromb Res 112 (2003) 13-18
62. Buller H.R., Davidson B.L., Decousus H., et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 140 (2004) 867-873